Clinical and pathological significance of the integrin α5β1 expression in endometrial adenocarcinoma

Abstract

Purpose: To investigate the integrin α5β1 expression in endometrial adenocarcinoma and its relation with tumor differentiation, invasion, metastasis and prognosis. Methods: The integrin α5β1 expression was detected in 92 cases of endometrial adenocarcinoma by immunohistochemistry technique (PAP method). Results: The expression of integrin α5β1 in 77.1% cases with endometrial adenocarcinoma were weaker or loss. The positive rate of integrin α5β1 was lower in poorly differentiated carcinoma group than in well differentiated group (P < 0.05). The positive rate of integrin α5β1 was lower in lymph-node metastatic group than in nonmetastatic group (P < 0.05). The five-year survival rate of integrin α5β1 positive group was higher in integrin α5β1 positive group (78.4%) than that in negative group (19.2%, P< 0.05). Conclusions: The weak or loss expression of integrin α5β1 was correlated with differentiation and metastasis of endometrial adenocarcinoma. The expression of integrin α5β1 may have prognostic value.